- Home
- GBCI vs MIRM Comparison
GBCI vs MIRM Comparison
Compare GBCI & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBCI | MIRM |
|---|---|---|
| Founded | 1955 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 1996 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GBCI | MIRM |
|---|---|---|
| Price | $47.46 | $97.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $53.60 | ★ $115.33 |
| AVG Volume (30 Days) | 767.8K | ★ 816.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | 18.45 | ★ 74.59 |
| EPS | ★ 1.99 | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $31.62 | $26.22 |
| Revenue Next Year | $8.37 | $21.77 |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.21 | $37.33 |
| 52 Week High | $53.99 | $109.28 |
Technical Indicators
Market Signals| Indicator | GBCI | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 62.82 | 59.26 |
| Support Level | $46.98 | $97.49 |
| Resistance Level | $50.20 | $107.51 |
| Average True Range (ATR) | 1.04 | 3.73 |
| MACD | 0.54 | 1.09 |
| Stochastic Oscillator | 87.45 | 88.41 |
Price Performance
Historical ComparisonAbout GBCI Glacier Bancorp Inc.
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.